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valuation of the Effect of Oral Verapamil
n Clinical Outcome and Angiographic
estenosis After Percutaneous Coronary Intervention
he Randomized, Double-Blind, Placebo-Controlled,
ulticenter Verapamil Slow-Release for Prevention of
ardiovascular Events After Angioplasty (VESPA) Trial
ans-Peter Bestehorn, MD,* Franz-Josef Neumann, MD,* Heinz Joachim Bu¨ttner, MD,*
eter Betz, MD, PHD,* Peter Stu¨rzenhofecker, MD,† Eberhard von Hodenberg, MD,‡
ntoine Verdun, MD,§ Laszlo Levai, MD,§ Jean Pierre Monassier, MD, Helmut Roskamm, MD*
ad Krozingen, Bad Neustadt, and Lahr, Germany; and Colmar and Mulhouse, France
OBJECTIVES We investigated the effect of oral verapamil on clinical outcome and angiographic restenosis
after percutaneous coronary intervention (PCI).
BACKGROUND Thus far, there is no established systemic pharmacologic approach for the prevention of restenosis
after PCIs. Five small studies reported encouraging results for calcium channel blockers.
METHODS Our randomized double-blind trial included 700 consecutive patients with successful PCI of
a native coronary artery. Patients received the calcium channel blocker verapamil, 240 mg twice
daily for six months, or placebo. Primary clinical end point was the composite rate of death,
myocardial infarction, and target vessel revascularization (TVR) during one-year follow-up; the
angiographic end point was late lumen loss at the six-month follow-up angiography.
RESULTS We obtained complete clinical follow-up in 95% of the patients, and scheduled angiography
was performed in 94%. The proportion of patients treated with stents was 83%. The primary
clinical end point was reached in 67 (19.3%) patients on verapamil and in 103 (29.3%)
patients on placebo (relative risk [RR] 0.66 [95% confidence interval (CI) 0.48 to 0.89]; p 
0.002). This difference between the groups was driven by TVR (17.5% with verapamil vs.
26.2% with placebo; RR 0.67 [95% CI 0.49 to 0.93]; p  0.006). Late lumen loss was 0.74
 0.70 mm with verapamil and 0.81  0.75 mm with placebo (p  0.11). Compared with
placebo, verapamil reduced the rate of restenosis 75% (7.8% vs. 13.7%; RR 0.57 [95% CI
0.35 to 0.92]; p  0.014).
CONCLUSIONS Verapamil compared with placebo improves long-term clinical outcome after PCI of native
coronary arteries by reducing the need for TVR. This was caused by a reduction in the rate
of high-grade restenosis. (J Am Coll Cardiol 2004;43:2160–5) © 2004 by the American
College of Cardiology Foundationp
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Phe long-term benefit from percutaneous coronary inter-
entions (PCI) is limited by restenosis (1). Despite intensive
esearch in recent years, it is still controversial whether any
ystemic drug therapy can prevent this adverse outcome. To
his end, various drugs with promising efficacy in animal
xperiments have been tested in patients. Yet, most of the
tudies failed to show an unequivocal beneficial effect of
ystemic drug therapy on restenosis. There is reasonable
kepticism whether systemic administration can achieve the
ocal drug levels needed to suppress restenosis (2–4).
Calcium channel blockers are among the few drugs with
romising results in the prevention of restenosis. The
From the *Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany; †Herz-und
efa¨ßklinik Bad Neustadt, Bad Neustadt, Germany; ‡Herz-Zentrum Lahr, Lahr,
ermany; §Clinic St. Joseph Colmar, Colmar, France; and Hospital Emil Mu¨ller,
ulhouse, France. Supported, in part, by a grant from Abbott GmbH & Co., KG
udwigshafen, Germany.
Manuscript received May 7, 2003; revised manuscript received January 2, 2004,ccepted February 10, 2004.utative antirestenotic properties of calcium channel block-
rs have been attributed to concentration-dependent inhi-
ition of smooth muscle cell transformation and prolifera-
ion after stimulation with platelet-derived growth factor
5–7). Meta-analysis (8) of five small studies (9–13) yielded
significant 30% relative reduction in the risk of restenosis
y calcium channel blockers as compared with placebo. This
nding, however, has not been tested in an adequately
owered trial. Therefore, we conducted the multicenter,
andomized, double-blind, placebo-controlled, Verapamil
low-Release for Prevention of cardiovascular Events After
ngioplasty (VESPA) trial to assess the effect of the
alcium channel blocker verapamil on clinical outcome and
ngiographic restenosis after PCI.
ETHODS
atients selection and stent placement. Patients of age
35 and80 years with successful PCI of a native coronary
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June 16, 2004:2160–5 Oral Verapamil and Restenosis After PCIrtery were eligible for the study. Successful intervention
as defined by residual stenosis 30% on visual estimation
nd—in case of stenting—desired position of stent. We
xcluded patients with restenotic lesions, occlusions, lesions
n bypass grafts, and left main location as well as patients
ith unstable angina, acute myocardial infarction (MI),
d-hoc and multistage PCI, insulin-dependent diabetes,
enal insufficiency, sick sinus syndrome, atrioventricular
ode block, congestive heart failure and/or left ventricular
jection fraction 40%, severe concomitant diseases, con-
raindications to verapamil, and patients with inability to
rovide informed consent for participation. The study was
pproved by the institutional ethical review board of each
ospital, and all patients gave written informed consent
efore inclusion in the study.
Although the use of stents was encouraged, the percuta-
eous treatment modality was left to the operator’s discre-
ion. All patients received aspirin 100 mg, once daily,
ndefinitely and, in case of stenting, ticlopidine 250 mg,
wice daily, or clopidogrel 75 mg, once daily, for four weeks.
hienopyridines were started immediately after the inter-
ention.
tudy protocol. We designed our study as a prospective,
ulticenter, randomized, double-blind, placebo-controlled
rial. Within 30 min after PCI, we assigned eligible patients
o receive either verapamil, 240 mg slow-release tablets, or
dentical-appearing placebo twice daily. At each participat-
ng center, allocation to the study treatment was based on
omputer-generated random numbers that were used for
ouble-blind labeling. In patients undergoing multivessel
CI (n 83), the most clinically relevant lesion was defined
s the study lesion at the time of randomization. The study
rug was started immediately after PCI and was continued
ntil three days before six-month follow-up angiography.
After PCI, we determined plasma concentrations of
reatine kinase and its MB isoenzyme systematically for
8 h. We scheduled outpatient visits at one and three
onths after randomization for clinical follow-up including
2-lead electrocardiogram recordings. Patients returned to
he hospital for routine angiographic restudy and clinical
valuation including bicycle ergometry at six months.
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CAD  coronary artery disease
CI  confidence interval
MI  myocardial infarction
MLD  minimal lumen diameter
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary
angioplasty
RR  relative risk
TVR  target vessel revascularization
VESPA  Verapamil Slow-Release for Prevention of
Cardiovascular Events After Angioplasty trialollow-up angiography was performed earlier if the patient (ad recurrent symptoms or signs of ischemia. Patients who
ad undergone angiography at4 months after recruitment
ithout meeting the criteria for a clinical end point were
ncouraged to undergo repeat angiography at six months.
t each follow-up visit, we assessed compliance by pill
ounts.
uantitative angiography. Angiographic images were
tored on compact discs (one center) or grabbed from cine
lms (other centers) and analyzed before the study was
nblinded. Quantitative analysis was performed as described
reviously (14–16). Using the same two orthogonal views
hroughout the study, we obtained minimal luminal diam-
ter (MLD), reference diameter, percent diameter stenosis,
nd the diameter of the maximally inflated balloon from the
nalysis system (Cardiovascular Angiographic Analysis Sys-
em, Department of Medical Informatics, University of
imburg, Limburg, the Netherlands).
Acute gain was calculated as the difference between
ost-stenting and predilation MLD, late loss as the differ-
nce between post-stenting MLD and MLD at follow-up,
et gain as the difference between MLD at follow-up, and
redilation MLD and loss index was calculated as the ratio
f late loss to acute gain. All measurements were performed
y the same blinded operator; intraobserver variability was
.10 mm for MLD and 2.58% for diameter stenosis.
tudy end points. Our clinical primary end point was the
ombined incidence of death, MI, and target vessel revas-
ularization (TVR). Myocardial infarction was defined as
he presence of new Q waves (40 ms) in two or more
ontiguous electrocardiographic leads or an elevation of
reatine kinase or its MB isoenzyme to at least 3  the
pper limit of normal (80 U/l, 10 U/l, respectively) in two
amples during hospitalization or to 2  the upper limit of
ormal after discharge. We defined TVR as coronary artery
ypass surgery or repeat percutaneous angioplasty involving
he treated vessel and performed for symptoms or signs of
schemia in the presence of angiographic restenosis (50%).
arget vessel revascularization by coronary artery bypass
urgery, which was indicated at the time of follow-up
ngiography, was counted as an event, even when performed
uring subsequent hospital admission. As our primary
ngiographic end point, we assessed late loss. We also
nalyzed other angiographic indexes of restenosis, including
oss index, percent diameter stenosis, and the incidence of
evere restenosis, defined as diameter stenosis 75%.
ample size estimation and statistical analysis. For cal-
ulation of sample size, we assumed a 25% incidence of our
rimary clinical end point (17). We designed the study to
ave a power of 80% to detect a 40% reduction in our
rimary clinical end point by verapamil as compared with
lacebo with a two-sided alpha value of 0.025. According to
hese assumptions, 325 patients were required in each
reatment arm. To account for losses to follow-up, we
ntended to include 700 patients. Assuming a normal
istribution with a standard deviation of 0.5 mm for late loss
17) and allowing for missing angiograms in 100 patients,
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Oral Verapamil and Restenosis After PCI June 16, 2004:2160–5his sample size gave us an 80% power to detect a 0.13 mm
ifference in late loss with a two-sided alpha value of 0.025.
All analyses were performed according to the intention-
o-treat principle. Data are presented as mean  SD or as
ounts or proportions. We assessed differences between the
roups with use of a two-sided chi-square test for categor-
cal variables. For continuous variables we used the unpaired
test. A value of p  0.05 in the two-tailed test was
onsidered to statistically significant. The impact of baseline
haracteristics and other pertinent covariables on the pri-
ary clinical end point was adjusted using multivariate
ogistic regression. To account for the double primary end
oint, we adjusted the level of significance for our primary
nd points to p  0.025. For all statistical analyses, we used
AS 6.12 software package (SAS Institute, Cary, North
arolina).
ESULTS
tudy cohort and follow-up. The trial population is
hown in Figure 1. The study enrolled 700 patients; 348
ere assigned to verapamil and 352 to placebo. A coronary
tent was placed in 581 patients (83%). The study groups
ere homogeneous with respect to baseline demographic,
Figure 1. Trial profile. PCI  percutaneous catheter intervention.linical, and angiographic characteristics (Tables 1 to 3). chirty-seven patients were lost to clinical follow-up, and
ve additional patients refused second angiography. Thir-
een patients of the verapamil group and 33 patients of
he placebo group underwent follow-up angiography
rematurely.
Of the patients on verapamil, 19.5% (68 of 348) discon-
inued their study medication because of constipation (n 
3), second- or a third-degree heart block (n  8), or other
ardiovascular side effects (n  37). In the placebo group,
he discontinuation rate was 15.6% (55 of 352). In addition,
1.8% (n  41) of the verapamil group and 10.8% (n  38)
f the placebo group had a pill count that differed by more
han 30% from the expected pill count.
linical events. The primary clinical end point was
eached in 19.3% (67 of 348) of the verapamil group and in
9.3% (103 of 352) of the placebo group (Table 4). Thus,
dverse cardiac events were significantly (p  0.002) fewer
n the verapamil group than in the placebo group with a
elative risk (RR) reduction by verapamil of 34% (Table 4).
he difference in the incidence of our primary end point was
riven by a reduction in TVRs (Table 4). There were no
ppreciable differences in the incidences of death or MI.
he risk reduction for the TVR by verapamil as compared
ith placebo was similar in patients receiving a stent and in
atients treated with plain percutaneous transluminal coro-
ary angioplasty (PTCA): (RR, 0.74 [95% confidence
able 1. Baseline Demographic and Clinical Characteristics of
he Study Cohort
Verapamil
(n  348)
Placebo
(n  352)
p
Value
ge (yrs) 60.6  11.3 60.1  11.8 0.52
omen 59 (17.0) 65 (18.5) 0.60
MI (kg/m2) 27.6  3.6 27.4  3.5 0.45
ctive smoker 74 (21.3) 84 (23.9) 0.41
amily history of CAD 122 (35.1) 128 (36.4) 0.72
ypercholesterolemia 278 (79.9) 285 (81.0) 0.72
ypertension 219 (62.9) 217 (61.6) 0.73
iabetes 49 (14.1) 45 (12.9) 0.62
ultivessel disease 167 (48.0) 158 (44.9) 0.41
revious balloon angioplasty 44 (12.6) 39 (11.1) 0.52
revious coronary bypass
operation
9 (2.6) 15 (4.3) 0.22
revious myocardial infarction 115 (33.1) 120 (34.1) 0.77
ata are expressed as mean value  SD or number of patients (%).
BMI  body mass index; CAD  coronary artery disease.
able 2. Medication at Discharge
Verapamil
(n  348)
Placebo
(n  352) p Value
spirin 338 (97.1) 342 (97.2) 0.98
hienopyridines 297 (85.3) 305 (86.6) 0.62
itrates 174 (50.0) 160 (45.5) 0.23
SE inhibitors 239 (68.7) 248 (70.5) 0.61
CE inhibitors 153 (44.0) 156 (44.3) 0.93
T-II receptor blockers 9 (2.6) 10 (2.8) 0.84
iuretics 26 (7.5) 35 (9.9) 0.25
ata are expressed as number of patients (%).
ACE  angiotensin-converting enzyme; AT-II  angiotensin-II; CSE holesterol synthesis enzyme.
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June 16, 2004:2160–5 Oral Verapamil and Restenosis After PCInterval (CI) 0.52 to 1.05]; p  0.05 vs. RR 0.50 [95% CI
.21 to 1.15]; p  0.06). In a multivariable logistic regres-
ion model that took into account baseline variables listed in
ables 1 and 3, the adjusted odds ratio was 0.52 (95% CI
.32 to 0.84; p  0.007) for the clinical primary end point
omparing both treatment strategies.
ngiographic indexes of restenosis. Mean late loss was
.74  0.70 mm in the verapamil group and 0.81  0.75
m in the placebo group (Table 5); thus, our primary
ngiographic end point did not reach statistical significance
p 0.11). The cumulative distribution of percent diameter
tenosis at follow-up (Fig. 2) shows a separation of the
urves in the region of more severe stenoses. Accordingly,
e found a significant reduction in the rate of high-grade
estenosis (75%) by verapamil as compared with placebo,
ut only a trend towards a reduction in restenosis rate
ccording to the 50% criterion (Table 5). Other indices of
estenosis confirmed the trend towards attenuated restenosis
y verapamil, but did not reach statistical significance either.
The differences in late loss between the verapamil and
lacebo groups were similar after stenting (0.82  0.69 mm
s. 0.90  0.72 mm; p  0.20) and after plain balloon
Table 3. Baseline Angiographic and Procedura
Complex lesions (AHA/ACC type B2, C)
Lesions per patient
Vessel size, mm
Before PCI
MLD, mm
Diameter stenosis, %
Procedural variables
Balloon-to-vessel ratio
Inflation pressure, atm
Stent placement
In-stented patients:
Number of stents per stented study lesion
Stented length, mm
After PCI
MLD, mm
Acute gain (mm)
Diameter stenosis, %
Data are expressed as mean value  SD or number of patie
AHA/ACC  American Heart Association/American Co
percutaneous coronary intervention.
Table 4. Clinical Events
Verapamil
(n  348)
Any cardiac event 67 (19.3)
Death or MI 6 (1.7)
Death 2 (0.6)
Nonfatal MI 4 (1.2)
TVR 61 (17.5)
PCI 58 (16.7)
CABG 3 (0.9)
Data are expressed as number of patients (%).
CABG  coronary artery bypass grafting; MI  myocarrelative risk; TVR  target vessel revascularization; CI  confidenngioplasty (0.36  0.64 mm vs. 0.41  0.72 mm; p 
.67), as were the risk reductions for high-grade restenosis
RR 0.56 [95% CI 0.33 to 0.97]; p 0.03 vs. RR 0.58 [95%
I 0.12 to 1.75]; p  0.30).
ISCUSSION
ur randomized, placebo-controlled multicenter trial inves-
igated the effect of verapamil on the clinical and angio-
raphic outcome after PCI. Verapamil, administered for six
onths after PCI, reduced the incidence of major adverse
ardiac events, our primary clinical end point, by reducing
he need for repeat TVR. Consistent with this outcome, we
ound a significant reduction in the incidence of high-grade
estenosis, although our primary angiographic end point,
ate loss, failed to show significant differences. Previous
rials on calcium channel blockers were flawed by small sizes
nd methodological issues, such as subjective evaluation of
estenosis. To our knowledge, our trial is the first adequately
owered study addressing the effect of verapamil on reste-
osis with the use of quantitative coronary angiography.
lthough the impact of verapamil on restenosis was con-
aracteristics of the Study Cohort
Verapamil
(n  348)
Placebo
(n  352) p Value
169 (48.6) 169 (48.0) 0.94
1.16 1.13 0.37
.92  0.55 2.90  0.54 0.62
.58  0.33 0.55  0.30 0.25
0.4  10.3 81.0  9.7 0.38
.07  0.18 1.09  0.18 0.19
1.8  2.9 12.2  3.0 0.18
290 (83.3) 291 (82.7) 0.82
.09  0.33 1.17  0.47 0.02
5.4  6.8 16.1  6.9 0.19
.51  0.51 2.47  0.50 0.29
.94  0.52 1.93  0.55 0.75
3.7  15.1 14.3  15.8 0.59
).
of Cardiology; MLD  minimum luminal diameter; PCI 
Placebo
 352) p Value RR (95% CI)
03 (29.3) 0.002 0.66 (0.48–0.89)
11 (3.1) 0.23 0.55 (0.20–1.49)
1 (0.3) 0.99 2.02 (0.11–119.0)
10 (2.8) 0.11 0.40 (0.13–1.29)
92 (26.2) 0.006 0.67 (0.49–0.93)
87 (24.8) 0.009 0.67 (0.48–0.94)
5 (1.4) 0.74 0.61 (0.09–3.09)
farction; PCI  percutaneous coronary intervention; RR l Ch
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Oral Verapamil and Restenosis After PCI June 16, 2004:2160–5iderably smaller than anticipated based on the earlier
tudies, the principle effect is confirmed. With the weight of
he present study, currently available evidence suggests that
alcium antagonists are capable of interfering with mecha-
isms involved in restenosis formation. Mechanisms that
ould be targeted by calcium antagonists include smooth
uscle cell transformation, and migration and proliferation,
s well as elaboration of extracellular matrix proteins (18–
0).
Our analyses, specifically the cumulative distributions of
ercent diameter stenosis, suggest a predominant effect of
erapamil in the prevention of excessive restenosis forma-
ion. Previous studies revealed a bimodal distribution of
estenosis formation after plain PTCA and after stenting
21). This bimodal distribution delineates two populations,
hich develop distinctively different degrees of lumen re-
arrowing. From our findings, it is conceivable that vera-
amil acts predominantly on the population with the
trongest propensity to renarrowing. In this population, the
ntiproliferative properties of verapamil that have been
escribed in experimental studies may become particularly
ffective.
tudy limitations. Of a large number of patients screened,
nly 6% were eventually included in the study. This was
argely due to the strict inclusion criteria avoiding high-risk
atients such as those with acute coronary syndromes and
atients who were unlikely to complete follow-up (Fig. 1).
otably, only 2.1% were excluded because of contraindica-
ions to verapamil. On the other hand, the dosage of
Table 5. Quantitative Angiographic Data at A
Verapamil
(n  321)
Late loss, mm 0.74  0.70
MLD, mm 1.77  0.72
Diameter stenosis, % 39.2  22.3
Loss index 0.38  0.37
Net gain, mm 1.20  0.73
Diameter stenosis 50% 82 (25.7)
Diameter stenosis 75% 25 (7.8)
Data are expressed as numbers (percentages) or mean value
Abbreviations as in Tables 3 and 4.
igure 2. Cumulative distribution curves for percent diameter stenosis at
ollow-up in the two treatment groups.erapamil had to be reduced or withdrawn in about one-
hird of the patients.
The possibility has to be considered that the reduction in
VR was caused by the antianginal properties of verapamil.
o reduce this effect, the study protocol mandated bicycle
rgometry before follow-up angiography and after discon-
inuation of study medication for three days. Nevertheless,
he role of antianginal properties of verapamil cannot be
ompletely ruled out. Although the majority of our patients
ere treated with stents, there was some admixture from
atients who underwent plain PTCA. The mechanisms of
estenosis differ substantially between the two treatment
odalities. Neointima formation accounts for about 90% of
he lumen loss after stenting (22,23). After plain PTCA,
eointima formation is less pronounced, and about two-
hirds of lumen loss are caused by early elastic recoil and late
essel shrinkage. We cannot assume a uniform action of
erapamil on each of these mechanisms. The low number of
atients treated with plain PTCA prevented the detection
f differences between the two percutaneous treatment
odalities, but may have contributed to scatter.
linical implications. Although the effect of verapamil on
estenosis formation was statistically detectable, its extent
as limited and has to be weighed against the disadvantages
f withholding beta-blockers. In the meantime, stents
eleasing antiproliferative agents have proven, by far, to be
ore powerful tools in the prevention of restenosis (24).
owever, these devices are costly, and there is concern that
he impairment of vascular healing processes after interven-
ion might pose a substantial risk of late thrombotic events
25). Therefore, there is continued interest in the search for
lternative approaches (26). To this end, the results of our
tudy demonstrate the potential that resides in systemic
dministration of antiproliferative agents.
eprint requests and correspondence: Dr. Hans-Peter Bestehorn,
erz-Zentrum Bad Krozingen, Su¨dring 15, 79189 Bad Krozingen,
ermany. E-mail: hans-peter.bestehorn@herzzentrum.de.
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